Mitochondrial ribosomal protein L9 (MRPL9)

Mitochondrial ribosomal protein L9 (MRPL9) is a structural component of the large 39S subunit of the mitochondrial ribosome, encoded by nuclear DNA and imported into mitochondria for assembly[1][9]. It is one of many mitochondrial ribosomal proteins (MRPs) contributing to mitochondrial protein synthesis, essential for oxidative phosphorylation and energy production in eukaryotic cells[2][4]. MRPL9 is implicated in the regulation of mitochondrial translation and cellular metabolism, and has gained attention as a contributor to cancer progression, particularly lung cancer, where its upregulation promotes cell proliferation and migration, likely through the c-MYC transcriptional pathway[2]. No direct pharmacological antagonists or modulators of MRPL9 are currently used in clinical practice. As a core ribosomal protein, MRPL9 is fundamentally required for mitochondrial biogenesis and function; thus, targeting this protein may pose significant safety risks due to disruption of cellular energy production.

Other names

Large ribosomal subunit protein bL9mMRPL9L9mtMRP-L9bL9m39S ribosomal protein L9, mitochondrialmitochondrial large ribosomal subunit protein bL9m

No established drug mechanisms specifically targeting MRPL9; mitochondrial ribosomal proteins remain experimental cancer targets